You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 19, 2025

Drug Price Trends for DEXTROAMP-AMPHETAMIN


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for DEXTROAMP-AMPHETAMIN

Average Pharmacy Cost for DEXTROAMP-AMPHETAMIN

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug NameNDCPrice/Unit ($)UnitDate
DEXTROAMP-AMPHETAMIN 10 MG TAB 13107-0070-01 0.22490 EACH 2024-12-18
DEXTROAMP-AMPHETAMIN 10 MG TAB 00527-1502-37 0.22490 EACH 2024-12-18
DEXTROAMP-AMPHETAMIN 10 MG TAB 11534-0192-01 0.22490 EACH 2024-12-18
DEXTROAMP-AMPHETAMIN 10 MG TAB 00185-0842-01 0.22490 EACH 2024-12-18
DEXTROAMP-AMPHETAMIN 10 MG TAB 00555-0972-02 0.22490 EACH 2024-12-18
DEXTROAMP-AMPHETAMIN 10 MG TAB 00406-8892-01 0.22490 EACH 2024-12-18
DEXTROAMP-AMPHETAMIN 10 MG TAB 00527-0762-37 0.22490 EACH 2024-12-18
>Drug Name>NDC>Price/Unit ($)>Unit>Date
Showing 1 to 7 of 7 entries

Market Analysis and Price Projections for Dextroamphetamine-Amphetamine

Market Overview

The global attention deficit hyperactivity disorder (ADHD) market, which includes drugs like dextroamphetamine-amphetamine, is experiencing significant growth driven by several key factors.

Rising Prevalence of ADHD

The global ADHD market was valued at USD 15.8 billion in 2023 and is projected to grow at a CAGR of over 5.1% from 2024 to 2032. This growth is largely attributed to the increasing prevalence of ADHD, with approximately 7 million children in the U.S. aged 3 to 17 years diagnosed with the condition, according to the CDC[1].

Advances in Diagnostic Technologies

Improved diagnostic tools and increased awareness among parents and healthcare professionals have led to a surge in ADHD diagnoses. Public health campaigns and educational programs have also played a crucial role in destigmatizing ADHD, prompting more individuals to seek diagnosis and treatment[1].

Market Segmentation

By Drug Type

The ADHD market is segmented into stimulants and non-stimulants. Dextroamphetamine-amphetamine falls under the stimulant category, which dominated the market with USD 11.2 billion in 2023. The stimulant segment is further bifurcated into amphetamine, methylphenidate, lisdexamfetamine, dexmethylphenidate, and dextroamphetamine[1].

By Age Group

The market is divided into children and adults, with the children segment accounting for a significant 67.1% market share in 2023. This indicates a high demand for ADHD medications among pediatric patients[1].

By Gender

The male segment dominated the market with USD 10.4 billion in 2023, reflecting a higher prevalence of ADHD among males[1].

By Dosage Form

The tablets segment, which includes dextroamphetamine-amphetamine tablets, dominated the market with USD 9.2 billion in 2023 and is expected to reach USD 14.2 billion within the forecast period[1].

Price Analysis

Current Pricing

The cost of dextroamphetamine-amphetamine varies based on dosage and form. For example, the cost for amphetamine/dextroamphetamine 10 mg oral tablets can range from $24 to $46 for a supply of 100 tablets, depending on the pharmacy[2].

Generic Drug Impact

The introduction of generic versions of ADHD medications has significantly impacted pricing. Generic approvals in 2021 led to substantial price reductions, with some drugs experiencing price drops of over 50% compared to their pre-generic prices. For instance, the price of amphetamine salts capsules (extended release) saw significant savings after generic approvals[3].

Regional Market Analysis

United States

The U.S. ADHD market is expected to grow at a 5.1% CAGR, reaching USD 10.2 billion by the end of 2032. This growth is driven by high diagnosis rates and the demand for innovative treatments[1].

Europe

Germany is experiencing robust growth in the European ADHD market, contributing to the overall regional growth[1].

Asia Pacific

The Asia Pacific region is witnessing substantial growth at a CAGR of 5.4% during the analysis period, driven by increasing awareness and improved diagnostic capabilities[1].

Latin America

Brazil is experiencing robust development in the Latin American market, reflecting growing healthcare infrastructure and awareness about ADHD[1].

Competitive Landscape

The ADHD market is highly competitive, with major pharmaceutical companies dominating the landscape. These companies are expanding their market presence through mergers, acquisitions, and partnerships. They are also investing in research and development to introduce new and innovative treatment options, including both stimulant and non-stimulant medications[1].

Key Trends and Drivers

  • Digital Health: Advances in digital health are facilitating easier access to healthcare professionals and contributing to the growth of the ADHD market[1].
  • Public Health Campaigns: Increased awareness and educational programs are destigmatizing ADHD, leading to more diagnoses and treatments[1].
  • Innovative Treatments: The development of new pharmacological and non-pharmacological treatments is driving market growth[1].

Price Projections

Given the current trends and the impact of generic drug approvals, here are some price projections for dextroamphetamine-amphetamine:

  • Short-Term: Prices are expected to remain relatively stable or see minor reductions due to the availability of generic options. For example, the price for 100 tablets of 10 mg amphetamine/dextroamphetamine could range from $24 to $46, with a potential to lean towards the lower end due to generic competition[2].
  • Long-Term: As more generic versions enter the market and competition increases, prices are likely to decrease further. The average price per tablet could drop significantly, similar to other drugs that saw price reductions post-generic approvals[3].

Key Takeaways

  • The global ADHD market is growing at a CAGR of over 5.1% from 2024 to 2032.
  • Dextroamphetamine-amphetamine is a key player in the stimulant segment, which dominated the market in 2023.
  • Generic drug approvals are significantly reducing prices, benefiting consumers.
  • Regional markets, especially in the U.S., Europe, Asia Pacific, and Latin America, are experiencing robust growth.
  • Major pharmaceutical companies are driving innovation and market expansion through strategic moves.

FAQs

1. What is the current market size of the global ADHD market? The global ADHD market was valued at USD 15.8 billion in 2023[1].

2. What is the projected CAGR for the ADHD market from 2024 to 2032? The ADHD market is projected to grow at a CAGR of over 5.1% from 2024 to 2032[1].

3. Which segment dominates the ADHD market by drug type? The stimulant segment, which includes dextroamphetamine-amphetamine, dominated the market with USD 11.2 billion in 2023[1].

4. How have generic drug approvals impacted the pricing of ADHD medications? Generic drug approvals have led to significant price reductions, with some drugs experiencing price drops of over 50% compared to their pre-generic prices[3].

5. What are the key drivers of the ADHD market growth? Key drivers include the rising global prevalence of ADHD, advances in diagnostic technologies, and the development of innovative treatment options, as well as increased awareness and digital health advancements[1].

Sources

  1. Global Attention Deficit Hyperactivity Disorder Market Share, 2024-2032 - GMI Insights
  2. Amphetamine/dextroamphetamine Prices, Coupons, Copay Cards - Drugs.com
  3. Estimating Cost Savings from New Generic Drug Approvals in 2021 - FDA
  4. IQVIA Report on Stimulant Trends from 2012 - 2022 - DEA Diversion Control Division
  5. Dextroamphetamine Sulfate Coupons & Prices - SingleCare

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.